The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: Extension of a lung cancer risk prediction model

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2462-2470

  El Zein, Randa A ^a   Lopez, Mirtha S ^a   D'Amelio, Anthony M ^a   Liu, Mei ^a,b   Munden, Reginald F ^a,c   Christiani, David ^d   Su, Li ^d   Tejera Alveraz, Paula ^d   Zhai, Rihong ^d   Spitz, Margaret R ^e   Etzel, Carol J ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Dan L Duncan Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BINUCLEATE SPORE; BINUCLEATED MICRONUCLEI; BINUCLEATED NUCLEOPLASMIC BRIDGE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; CYTOKINESIS; CYTOKINESIS BLOCKED MICRONUCLEUS ASSAY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MALE; MICRONUCLEUS; MICRONUCLEUS TEST; MIDDLE AGED; MULTICENTER STUDY; PREDICTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; SPITZ RISK PREDICTION MODEL; UNITED STATES; GENETICS; LUNG NEOPLASMS;

CYTOKINESIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES;

EID: 84920178375     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0462     Document Type: Article

References (41)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, Inc; 2013.
2. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genomewide association scan of tag SNPs identi fies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-22.
3. Doll R, Peto R. Cigarette-smoking and bronchial-carcinoma - dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Commun Health 1978;32:303-13.
4. Hoffmann D, Hoffmann I, El Bayoumy K. Less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 2001;14:767-90.
5. Sellers TA, Potter JD, Bailey-Wilson JE, Rich SS, Rothschild H, Elston RC. Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. Cancer Res 1992;52:2694-7.
6. Fenech M. Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov Today 2002;7:1128-37.
7. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science 1991;254:1153-60.
8. Liou SH, Lung JC, Chen YH, Yang T, Hsieh LL, Chen CJ, et al. Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Cancer Res 1999;59:1481-4.
9. Bonassi S, Hagmar L, Stromberg U, Montagud AH, Tinnerberg H, Forni A, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res 2000;60:1619-25.
10. Bonassi S, Znaor A, Norppa H, Hagmar L. Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective. Cytogenet Genome Res 2004;104:376-82.
11. Smerhovsky Z, Landa K, Rossner P, Brabec M, Zudova Z, Hola N, et al. Risk of cancer in an occupationally exposed cohort with increased level of chromosomal aberrations. Environ Health Perspect 2001;109:41-5.
12. Tucker JD, Preston RJ. Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat Res 1996;365:147-59.
13. Fenech M. The in vitro micronucleus technique. Mutat Res 2000;455:81-95.
14. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007;2:1084-104.
15. Umegaki K, Fenech M. Cytokinesis-block micronucleus assay in WIL2-NS cells: a sensitive system to detect chromosomal damage induced by reactive oxygen species and activated human neutrophils. Mutagenesis 2000;15:261-9.
16. Stewenius Y, Gorunova L, Jonson T, Larsson N, Höglund M, Mandahl N, et al. Structural and numerical chromosome changes in colon cancer develop through telomere mediated anaphase bridges, not through mitotic multipolarity. Proc Natl Acad Sci U S A 2005;102:5541-6.
17. Fenech M. Biomarkers of genetic damage for cancer epidemiology. Toxicology 2002;181-182:411-6.
18. El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR. Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res 2006;66:6449-56.
19. El-Zein RA, Fenech M, Lopez MS, Spitz MR, Etzel CJ. Cytokinesisblocked micronucleas cytome assay biomarkers identify lung cancer cases amongst smokers. Cancer Epidemiol Biomarkers Prev 2008;17:1111-9.
20. McHugh MK, Lopez MS, Ho CH, Spitz MR, Etzel CJ, El-Zein RA. Use of the cytokinesis-blocked micronucles assay to detect gender differences and genetic instability in a lung cancer case control study. Cancer Epidemiol Biomarkers Prev 2013;22:135-45.
21. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26.
22. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8.
23. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270-6.
24. Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst 2011;103:1058-68.
25. Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Ostergaard JN, et al. A risk model for lung cancer incidence. Cancer Prev Res 2012;5:834-46.
26. Raji OY, Agbaje OF, Duffy SW, Cassidy A, Field JK. Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: the Liverpool Lung Project. Cancer Prev Res 2010;3:664-9.
27. Spitz MR, Amos CI, D'Amelio A Jr, Dong Q, Etzel C. Re: discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2009;101:1731-2.
28. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res 2008;1:250-4.
29. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985;147:29-36.
30. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E, et al. HUMN Project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 2003;534:65-75.
31. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. StatMed 2008;27:157-72.
32. D'Amelio A Jr, Cassidy A, Asomaning K, Raji OY, Duffy SW, Field JK, et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer 2010;103:423-9.
33. Fields J, Chen Y, Marcus MW, Mcronald FE, Raji OY, Duffy SW. The contribution of risk prediction models to early detection of lung cancer. J Surg Oncol 2013;108:304-11.
34. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
35. Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 2009;101:959-63.
36. Hagmar L, Bonassi S, Strömberg U, Mikoczy Z, Lando C, Hansteen IL, et al. Cancer predictive value of cytogenetic markers used in occupational health surveillance programs. Recent Results Cancer Res 1998;154:177-84.
37. Ceppi M, Biasotti B, Fenech M, Bonassi S. Human population studies with the exfoliated buccal micronucleus assay: statistical and epidemiological issues. Mutat Res 2010;705:11-9.
38. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. Nat Med 2012;18:1630-8.
39. Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova EV, Pan Y, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012;482:53-8.
40. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
41. NLST: National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.